Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Dianthus Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $89.45
+98% since the alert
$41.21 → $81.52
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS